|Bid||103.29 x 800|
|Ask||104.99 x 1000|
|Day's range||103.12 - 104.93|
|52-week range||85.58 - 131.73|
|Beta (5Y monthly)||1.12|
|PE ratio (TTM)||44.98|
|Earnings date||25 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||116.68|
Edwards Lifesciences (EW) posts Q2 earnings in line with the Zacks Consensus Estimate, with robust performances across all product groups driving the top line.
With me on today's call are Mike Mussallem, chairman and chief executive officer; and Scott Ullem, chief financial officer. Also joining us for the Q&A portion of the call today will be Larry Wood, our global leader of TAVR; Bernard Zovighian, our global leader of TMTT; and Daveen Chopra, our global leader of Surgical Structural Heart.
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?